Title:
化合物
Document Type and Number:
Japanese Patent JP2007523905
Kind Code:
A
Abstract:
Compounds of Formula (I) wherein: R1 is methyl; R2 is selected from -C (O) NR4R5, SO2NR4R5, S (O) pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C) alkyl and HET-2; R5 is hydrogen or (1-4C) alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them and processes for their preparation are also described.
Inventors:
John stone, craig
McKellecher, Darren
Pike, Kurt Gordon
McKellecher, Darren
Pike, Kurt Gordon
Application Number:
JP2006553657A
Publication Date:
August 23, 2007
Filing Date:
February 15, 2005
Export Citation:
Assignee:
AstraZeneca Activrag
International Classes:
C07D213/75; A61K31/415; A61K31/42; A61K31/426; A61K31/427; A61K31/4402; A61K31/454; A61K31/496; A61K31/4965; A61K31/5377; A61K31/551; A61P3/10; A61P43/00; C07D231/38; C07D231/40; C07D241/20; C07D241/28; C07D261/14; C07D263/48; C07D277/20; C07D277/46; C07D285/08; C07D285/12; C07D285/135; C07D403/12; C07D405/12; C07D413/12; C07D417/04; C07D417/12
Attorney, Agent or Firm:
Kazuo Shamoto
Shinjiro Ono
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Takumi Terachi
Shinjiro Ono
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Takumi Terachi